Conv. Plasma
Nigella Sativa

All ivermectin studies
Meta analysis
study COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 90% Improvement Relative Risk ICU admission 72% Discharge 80% Time to viral- 59% Ivermectin for COVID-19  Akhtar et al.  LATE TREATMENT Is late treatment with ivermectin beneficial for COVID-19? Retrospective 423 patients in Pakistan Lower mortality (p<0.0001) and ICU admission (p=0.00061) Akhtar et al., The Professional Medica.., Sep 2022 Favors ivermectin Favors control

Does ivermectin reduce COVID-19 mortality and progression of disease severity? – A retrospective study

Akhtar et al., The Professional Medical Journal, doi:10.29309/TPMJ/2022.29.09.6634
Sep 2022  
  Source   PDF   All   Meta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
*, now known with p < 0.00000000001 from 100 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
Retrospective 423 patients in Pakistan, 216 receiving 6 day treatment, showing lower mortality, lower ICU admission, and faster viral clearance with treatment. Limited baseline information per group is provided. There were more severe patients in the ivermectin group. Logistic regression results are mentioned without full details. The difference in mortality was not statistically significant in logistic regression.
This study is excluded in meta analysis: pending additional information from authors.
risk of death, 90.4% lower, RR 0.10, p < 0.001, treatment 2 of 216 (0.9%), control 20 of 207 (9.7%), NNT 11.
risk of ICU admission, 71.6% lower, RR 0.28, p < 0.001, treatment 8 of 216 (3.7%), control 27 of 207 (13.0%), NNT 11.
risk of no hospital discharge, 79.6% lower, RR 0.20, p < 0.001, treatment 10 of 216 (4.6%), control 47 of 207 (22.7%), NNT 5.5.
time to viral-, 58.8% lower, relative time 0.41, p < 0.001, treatment mean 8.39 (±2.04) n=216, control mean 20.38 (±6.32) n=207.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Akhtar et al., 1 Sep 2022, retrospective, Pakistan, peer-reviewed, mean age 51.9, 9 authors, dosage 12mg days 1-6. Contact:
This PaperIvermectinAll
Does ivermectin reduce COVID-19 mortality and progression of disease severity? – A retrospective study.
Tehseen Akhtar, Amber Hanif, Pyar Ali, Muhammad Hussain Haroon, Nimra Akram, Muhammad Umar Raza, Khalid Imran, Nimra Shakeel, Ramsha Shakeel
The Professional Medical Journal, doi:10.29309/tpmj/2022.29.09.6634
Material & Methods: Medical records of 423 patients during a selected duration of 6 months were reviewed. Patients were stratified into two groups based on whether or not they received a 6-day course of ivermectin in addition to the standard treatment for COVID-19. Primary outcome measures were rate of mortality, days from the start of treatment to negative SARS-CoV-2 PCR, and rate of step-up to the intensive care unit. Results: Patients who received ivermectin required a lesser number of days (8.39 days ± 2.04) to become COVID negative than the patients who didn't receive ivermectin (20.38 days ± 6.32), (p < 0.001). Multinomial logistic regression showed that the patients who were given ivermectin for COVID 19 infection were four times more likely to be discharged home than stepping up to ICU. The ICU step-up rate in the ivermectin group was found to be 3.7% compared to 13.04% in the non-ivermectin group. No significant differences in mortality were found. Conclusion: Treatment with ivermectin in COVID-19 infection is associated with improved outcomes in terms of reduction in duration of illness as well as the progression of disease severity.
Adejumo, Impact of COVID-19 pandemic on renal care services in Nigeria, Pan Afr Med J, doi:10.11604/pamj.supp.2020.35.24403
Behera, Patro, Singh, Chandanshive, Kumar et al., Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study, doi:10.1101/2020.10.29.20222661
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res, doi:10.1042/bj20120150
Chen, Klein, Garibaldi, Li, Wu et al., Aging in COVID-19: Vulnerability, immunity and intervention, Ageing Res Rev, doi:10.1016/j.arr.2020.101205
Clinic, None, Mayo Clin Proc, doi:10.1016/j.mayocp.2020.04.010
Cohen, Hall, John, Rapoport, The Early Natural History of SARS-CoV-2 Infection: Clinical Observations from an Urban, Ambulatory COVID
Dr, Ruth, Pfau, Hospital, None
Inciardi, Adamo, Lupi, Cani, Pasquale et al., Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy, Eur Heart J, doi:10.1093/eurheartj/ehaa388
Kumanan, Rajasooriyar, Guruparan, Sreeharan, The Impact of COVID-19 on the Delivery of Critical Health Care: Experience from a Non-High-Income Country, Asia Pac J Public Health, doi:10.1177/1010539520963626
Lespine, Alvinerie, Sutra, Pors, Chartier, Influence of the route of administration on efficacy and tissue distribution of ivermectin in goat, Vet Parasitol, doi:10.1016/j.vetpar.2004.11.028
Lippi, Wong, Henry, Hypertension in patients with coronavirus disease 2019 (COVID-19): A pooled analysis, Pol Arch Intern Med, doi:10.20452/pamw.15272
Lv, Liu, Wang, Dang, Qiu et al., Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo, Antiviral Res, doi:10.1016/j.antiviral.2018.09.010
Mbbs, Dr, None
Mbbs, Dr, None
Mbbs, Dr, None
Mbbs, Dr, None
Mbbs, Medical Officer, Ruth, Pfau, Hospital, None
Mbbs, Officer, Ruth, Pfau, Hospital, None
Mbbs, Officer, Ruth, Pfau, Hospital, None
Mbbs, Officer, Ruth, Pfau, Hospital, None
Muniyappa, Gubbi, COVID-19 pandemic, coronaviruses, and diabetes mellitus, Am J Physiol Endocrinol Metab, doi:10.1152/ajpendo.00124.2020
Patt, Gordan, Diaz, Okon, Grady et al., Impact of COVID-19 on Cancer Care: How the pandemic is delaying cancer diagnosis and treatment for American seniors, JCO Clin Cancer Inform, doi:10.1200/cci.20.00134
Rajter, Sherman, Fatteh, Vogel, Sacks et al., Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019: The Ivermectin in COVID Nineteen Study, Chest, doi:10.1016/j.chest.2020.10.009
Santos, Natural history of COVID-19 and current knowledge on treatment therapeutic options, Biomed Pharmacother, doi:10.1016/j.biopha.2020.110493
Wagstaff, Sivakumaran, Heaton, Harrich, Jans, Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem J, doi:10.1042/bj20120150
Wang, Lv, Wang, Qiu, Yang, Ivermectin treatment inhibits the replication of Porcine circovirus 2 (PCV2) in vitro and mitigates the impact of viral infection in piglets, Virus Res, doi:10.1016/j.virusres.2019.01.010
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop